Bioorganic & Medicinal Chemistry 2010-07-15

Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase.

Gian Filippo Ruda, Gordon Campbell, Vincent P Alibu, Michael P Barrett, Ruth Brenk, Ian H Gilbert

文献索引:Bioorg. Med. Chem. 18 , 5056-62, (2010)

全文:HTML全文

摘要

The enzyme 6-phosphogluconate dehydrogenase is a potential drug target for the parasitic protozoan Trypanosoma brucei, the causative organism of human African trypanosomiasis. This enzyme has a polar active site to accommodate the phosphate, hydroxyl and carboxylate groups of the substrate, 6-phosphogluconate. A virtual fragment screen was undertaken of the enzyme to discover starting points for the development of inhibitors which are likely to have appropriate physicochemical properties for an orally bioavailable compound. A virtual screening library was developed, consisting of compounds with functional groups that could mimic the phosphate group of the substrate, but which have a higher pKa. Following docking, hits were clustered and appropriate compounds purchased and assayed against the enzyme. Three fragments were identified that had IC50 values in the low micromolar range and good ligand efficiencies. Based on these initial hits, analogues were procured and further active compounds were identified. Some of the fragments identified represent potential starting points for a medicinal chemistry programme to develop potent drug-like inhibitors of the enzyme.Copyright (c) 2010 Elsevier Ltd. All rights reserved.


相关化合物

  • DL-2-(3-噻吩基)-...

相关文献:

Proton magnetic resonance studies of bradykinin antagonists.

1993-08-01

[Biopolymers 33 , 1237-1247, (1993)]

Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures.

2000-03-07

[Biochemistry 39 , 2384-2391, (2000)]

更多文献...